THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Peripheral Arterial DiseaseClaudicationClaudication, IntermittentVascular OcclusionVascular CalcificationVascular DiseasesOsteoarthritis
Interventions
DIETARY_SUPPLEMENT

SPM Emulsion, Dose-modality

"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"

DIETARY_SUPPLEMENT

SPM Softgel, Dose-Modality

Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration

DIETARY_SUPPLEMENT

Placebo Softgel

Days 43-47: 4 Placebo softgel; Day 48-64 Washout

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT02719665 - THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease | Biotech Hunter | Biotech Hunter